for more information, CLICK HERE
Neovacs is a French biotechnology company focused on the development of Kinoids, therapeutic vaccines for the treatment of autoimmune and inflammatory diseases and cancer.
The goal of the Kinoid approach is enable patients to have a superior quality of life by providing access to safe treatments with sustained efficacy.
EUR 8 million capital increase successfully completed 01 June 2016 -
Capital increase with preferential subscription rights